Market Currents
Dendreon (DNDN): Q2 EPS of $0.61 misses by $0.02. Revenue of $80M misses by $6M. Company...
-
Monday, July 30, 2012, 4:39 PM ETDendreon (DNDN): Q2 EPS of $0.61 misses by $0.02. Revenue of $80M misses by $6M. Company announces strategic restructuring. Shares currently halted AH. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 3 comments:
http://reut.rs/JUge6s
The true test of Provenge's worth can only be ascertained by giving it as a first-line treatment without requiring participants to have hormone-refractory PCa.